FibroBiologics is pursuing a development program for FSdC spheroids with the goal of advancing to clinical trials. The data includes comprehensive preclinical pharmacology and efficacy assessments ...
TipRanks on MSN
FibroBiologics announces preclinical results for FSDC
FibroBiologics (FBLG) announced preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement ...
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti ...
HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the Group") is pleased to announce the official signing of a tripartite ...
Experiments reveal that a time-dependent epistatic interaction influences how mice respond to opioids, and that intracellular fibroblast growth factors also influence opioid sensitivity.
This article is based on a poster originally authored by Fiona Leslie, Chloe Whiting, and Megan Webster. TGF-β1-mediated activation of fibroblasts, their transition to α-SMA-expressing myofibroblasts, ...
Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback